SACRAMENTO, Calif., Aug.21, 2012 /PRNewswire/ -- Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world's largest stem cell bank, are launching the first FDA-approved clinical trial to assess the use of a child's own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
(Photo:http://photos.prnewswire.com/prnh/20120821/MM59477)
(Logo:http://photos.prnewswire.com/prnh/20120216/AQ54476LOGO)
According to the Centers for Disease Control and Prevention, autism spectrum disorders impact one in 88 children in the U.S., and one in 54 boys.1 The condition is thought to have multiple risk factors including genetic, environmental and immunological components.
"This is the start of a new age of research in stem cell therapies for chronic diseases such as autism, and a natural step to determine whether patients receive some benefit from an infusion of their own cord blood stem cells," said Michael Chez, M.D., director of Pediatric Neurology with the Sutter Neuroscience and principal study investigator. "I will focus on a select portion of children diagnosed with autism who have no obvious cause for the condition, such as known genetic syndromes or brain injury."
The study will enroll 30 children between the ages of two and seven, with a diagnosis of autism who meet the inclusion criteria for the study. Enrolled participants will receive two infusionsone of the child's own cord blood stem cells and one of a placeboover the course of 13 months. Both the participants and the lead investigators will be blinded from knowing the content of each infusion. To ensure the highest quality and consistency in cord blood stem cell processing, storage and release for infusion, CBR is the only family stem cell bank providing units from clients for the study.
For information on study, visit http://www.cordblood.com/autism.
Study Rationale
A newborn's umbilical cord blood contains a unique population of stem cells that have been used for more than 20 years in medical practice to treat certain cancers, blood diseases and immune disorders. When patients undergo a stem cell transplant for these conditions, the stem cells effectively rebuild the blood and immune systems.
Read more:
Autism and Cord Blood Stem Cells: FDA Gives Green Light for Groundbreaking Clinical Trial